Eli Lilly's Weight Loss Boom Hits an Uneven Road Eli Lilly has been riding high on the success of its GLP 1 weight loss medications. However, recent numbers suggest that the trend may be plateauing.
According to a report, employer coverage of these medicines has dropped from 72% in 2025 to 60% in 2026. This decline represents a fundamental shift in the way employers approach prescription costs.
For years, companies have been willing to foot the bill for expensive medications like Zepbound and Mounjaro, hoping that long term health benefits would justify the expense.